Scott McDonald

Boston Scientific’s interventional oncology and embolization (IO&E) franchise is focused on innovating new therapies that drive better outcomes for patients suffering from cancer. Looking beyond traditional medical devices, this team is asking fundamentally different questions to help advance therapy development initiatives and expand the company’s cancer care portfolio. In this session, R&D, Clinical and Commercial leaders from Boston Scientific will discuss how the company is taking a collaborative approach to advancing the future of interventional oncology.